Tumor ThrombusTUMOR THROMBUSNCT07748234
Role of Anticoagulation in the Management of Tumor Thrombus
An observational study of Tumor Thrombus, run by Children's Hospital Medical Center, Cincinnati at 1 site in United States.
Trial summary
The purpose of this study is to conduct a retrospective review of oncology patients with a diagnosis of any solid tumor and lymphoma to identify a cohort with radiographically reported tumor thrombus or tumor compression of vasculature. Read more about this study
- Who is it for?
- Ages 0 months to 40 years
- Conditions the study is for
- Tumor Thrombus
- How many people
- 1,900 participants
- Where
- 1 siteUnited States
- Study dates
- 26 Jan 2026to 1 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 0 months to 40 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: All individuals evaluated by Cincinnati Children's Hospital Medical Center Oncology program with a diagnosis of solid tumor and lymphoma (including osteosarcoma, Ewing sarcoma, Wilms tumor, hepatoblastoma, neuroblastoma, Hodgkin's and non-Hodgkin's lymphoma) since the initiation of EPIC medical record at CCHMC January 01, 2010 - January 01, 2026, and who are identified radiographically as having thrombus will have further review to determine if they have tumor thrombus or vascular compression for cohort inclusion.
Who may be able to join
- All Cincinnati Children's Hospital Medical Center (CCHMC) Oncology patients in the cancer registries (ACCRN07 CCHMC IRB #2008-1609 and the COG Registry CCHMC IRB # 2019-0616) identified as having a solid tumor and lymphoma (including osteosarcoma, Ewing sarcoma, Wilms tumor, hepatoblastoma, neuroblastoma, Hodgkin's and non-Hodgkin's lymphoma) diagnosis, and who, on review of radiographic study reports, have mention of tumor thrombus or vascular compression since January 01, 2010 - January 01, 2026, between the ages of 0 and 40 years old.
Who cannot join
- Cancer diagnosis other than a lymphoma or solid tumor Absence of tumor thrombus or vascular compression mentioned in radiographic reports stored at CCHMC (EPIC © 2020 Epic Systems Corporation). Lack of medical records available at CCHMC for review
Trial locations and contacts
1 site in 1 country.
United States1 site
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229
About this study
The purpose of this study is to conduct a retrospective review of oncology patients with a diagnosis of any solid tumor and lymphoma to identify a cohort with radiographically reported tumor thrombus or tumor compression of vasculature. Clinical and radiographic data will be collected on this cohort to understand the incidence and management of tumor thrombus or vascular compression, as well as relevant clinical outcomes, including bleeding, thrombus extension or embolism, and mortality.
Read the detailed description
Identify and characterize (by clinical, demographic, and radiographic data) pediatric and AYA solid tumor oncology patients with radiographic evidence of tumor thrombus.
Assess clinical outcomes (bleeding, thrombus resolution, thrombus extension or embolization, and mortality related to anticoagulation treatment vs non-treatment of identified tumor thrombus.
Identify and characterize pediatric and AYA solid tumor patients with a tumor compressing a vascular structure without thrombosis, as identified by review of radiographic reports.
- Conditions
- Tumor Thrombus
What is being measured
The primary outcome is the main question the study is designed to answer.
Anticoagulation or vascular intervention
Documentation in medical record of patient being placed on prophylactic or therapeutic anticoagulation or requiring therapeutic intervention (such as thrombectomy graft, stent, thrombolysis, or venoplasty)
Measured: Baseline through study completion, an average of 1 year
Clinical bleeding event
Major and clinically relevant non-major bleeding per ISTH definition
Measured: Baseline through study completion, an average of 1 year
Thrombus extension
Documented episode of thrombus extension or embolism, or bland thrombus formation
Measured: Baseline through study completion, an average of 1 year
Secondary outcomes (3)
Stage of oncologic disease at diagnosis
As indicated by local vs metastatic disease spread
Measured: Baseline through study completion, an average of 1 year
New vs relapsed oncologic disease
Patient presenting with a new diagnosis vs relapsed disease when tumor thrombus identified
Measured: Baseline through study completion, an average of 1 year
Disease status at last follow up
- Patient alive with no evidence of disease, alive with disease, dead of disease, died of other causes, lost to follow up
Measured: Baseline through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Aug 2026
- Study start26 Jan 2026
- Primary completion1 Dec 2026 (estimated)
- Study completion1 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Tumor ThrombusStudies of the same condition, open and under way.
- More trials run by Children's Hospital Medical Center, CincinnatiThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 1,900 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Lindsay Haacker, MD, Principal investigator, Children's Hospital Medical Center, Cincinnati
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07748234
- Sponsor's protocol ID
- TUMOR THROMBUS
- Acronym
- TUMOR THROMBUS
- Status last verified
- Jun 2026
- First submitted
- 2 Jun 2026
- Last updated
- 5 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Role of Anticoagulation in the Management of Tumor Thrombus
- ClinicalTrials.gov ID
- NCT07748234
- Acronym / sponsor ID
- TUMOR THROMBUS / TUMOR THROMBUS
- Conditions
- Tumor Thrombus
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,900 participants (estimated)
- Lead sponsor
- Children's Hospital Medical Center, CincinnatiUniversity, hospital or other
- Study start
- 26 Jan 2026 (actual)
- Primary completion
- 1 Dec 2026 (estimated)
- Study completion
- 1 Dec 2027 (estimated)
- First posted
- 5 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to conduct a retrospective review of oncology patients with a diagnosis of any solid tumor and lymphoma to identify a cohort with radiographically reported tumor thrombus or tumor compression of vasculature. Clinical and radiographic data will be collected on this cohort to understand the incidence and management of tumor thrombus or vascular compression, as well as relevant clinical outcomes, including bleeding, thrombus extension or embolism, and mortality.
Detailed description
Identify and characterize (by clinical, demographic, and radiographic data) pediatric and AYA solid tumor oncology patients with radiographic evidence of tumor thrombus.
Assess clinical outcomes (bleeding, thrombus resolution, thrombus extension or embolization, and mortality related to anticoagulation treatment vs non-treatment of identified tumor thrombus.
Identify and characterize pediatric and AYA solid tumor patients with a tumor compressing a vascular structure without thrombosis, as identified by review of radiographic reports.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 0 months to 40 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- All individuals evaluated by Cincinnati Children's Hospital Medical Center Oncology program with a diagnosis of solid tumor and lymphoma (including osteosarcoma, Ewing sarcoma, Wilms tumor, hepatoblastoma, neuroblastoma, Hodgkin's and non-Hodgkin's lymphoma) since the initiation of EPIC medical record at CCHMC January 01, 2010 - January 01, 2026, and who are identified radiographically as having thrombus will have further review to determine if they have tumor thrombus or vascular compression for cohort inclusion.
Key inclusion criteria (1 listed)
- All Cincinnati Children's Hospital Medical Center (CCHMC) Oncology patients in the cancer registries (ACCRN07 CCHMC IRB #2008-1609 and the COG Registry CCHMC IRB # 2019-0616) identified as having a solid tumor and lymphoma (including osteosarcoma, Ewing sarcoma, Wilms tumor, hepatoblastoma, neuroblastoma, Hodgkin's and non-Hodgkin's lymphoma) diagnosis, and who, on review of radiographic study reports, have mention of tumor thrombus or vascular compression since January 01, 2010 - January 01, 2026, between the ages of 0 and 40 years old.
Key exclusion criteria (1 listed)
- Cancer diagnosis other than a lymphoma or solid tumor Absence of tumor thrombus or vascular compression mentioned in radiographic reports stored at CCHMC (EPIC © 2020 Epic Systems Corporation). Lack of medical records available at CCHMC for review
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Anticoagulation or vascular intervention
Time frame: Baseline through study completion, an average of 1 year
Documentation in medical record of patient being placed on prophylactic or therapeutic anticoagulation or requiring therapeutic intervention (such as thrombectomy graft, stent, thrombolysis, or venoplasty)
Clinical bleeding event
Time frame: Baseline through study completion, an average of 1 year
Major and clinically relevant non-major bleeding per ISTH definition
Thrombus extension
Time frame: Baseline through study completion, an average of 1 year
Documented episode of thrombus extension or embolism, or bland thrombus formation
3 secondary outcomes
Stage of oncologic disease at diagnosis
Time frame: Baseline through study completion, an average of 1 year
New vs relapsed oncologic disease
Time frame: Baseline through study completion, an average of 1 year
Disease status at last follow up
Time frame: Baseline through study completion, an average of 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Aug 2026.
Related trials for Tumor Thrombus
RecruitingPhase 2
SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis
HCC
RecruitingPhase 3
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
Venous Thromboembolism (VTE)
RecruitingPhase 3
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
Cancer-Associated Thrombosis (CAT)
Active, not recruiting
Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma
Pancreatic Cancer, Advanced Pancreatic Ductal Adenocarcinoma
Not yet recruitingObservational study
Construction and Multicenter External Validation of an Early Warning Model for Asymptomatic PICC-related Upper Extremity Venous Thrombosis in Cancer Patients Based on LASSO-XGBoost
PICC-associated Thrombosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lindsay Haacker, MD principal investigator
Children's Hospital Medical Center, Cincinnati
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Tumor Thrombus, run by Children's Hospital Medical Center, Cincinnati at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 5 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Anticoagulation or vascular intervention (time frame: Baseline through study completion, an average of 1 year). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Aug 2026.